Tetanus booster vaccine to study immune cells in autoimmune disease patients
Tests a tetanus booster vaccine in adults with lupus, sclerosis or arthritis.
Key facts
- Who runs it
- Leids Universitair Medisch Centrum (LUMC)
- Where
- Leiden, NetherlandsSee the site
- Trial code
- Registry title
- Investigating the (autoreactive) B cell compartment in antibody-mediated autoimmune diseases in comparison with the recall Tetanus Toxoid response
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 96 people, planned
- Started
- 1 Oct 2025
- Expected to end
- 30 Sept 2028
- Type of study
- Interventional
- Record updated
- 8 July 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with systemic sclerosis, systemic lupus erythematosus or rheumatoid arthritis, and healthy volunteers. All get one tetanus booster vaccine so blood B cells can be studied.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Systemic sclerosis, systemic lupus erythematosus or rheumatoid arthritis, meeting the classification criteria for the diagnosis. Healthy volunteers can also join.
- Earlier treatment
- Must have finished the primary tetanus toxoid vaccination series. Must not have had B cell depleting or modifying therapy (Rituximab, Belimumab, Cyclophosphamide, Tocilizumab, Abatacept) in the 12 months before joining. Must not have had a tetanus vaccine or booster in the past 24 months.
Main reasons for not taking part
- Pregnant at the time of joining
- Allergy to the tetanus vaccine or its ingredients, or a severe reaction to an earlier dose
- Tetanus vaccine or booster in the past 24 months
- Treatment with Rituximab, Belimumab, Cyclophosphamide, Tocilizumab or Abatacept in the past 12 months
- Needing to donate 50 mL of blood or more in the first four weeks for another reason
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- ≥ 18 years of age
- able to understand the patient information form and to provide written informed consent
- willing to receive a single, one-time booster vaccination against tetanus toxoid
- having completed a primary vaccination regime against tetanus toxoid
Who cannot take part
- individuals unwilling to provide sufficient information on their current health status required to assess eligibility, with the most relevant information being the presence/absence or prior history of an autoimmune disease, vaccination history, or the current or recent use of immunosuppressive drugs
- who are or have been treated with specific B cell depleting/modifying therapies (Rituximab, Belimumab, Cyclophosphamide, Tocilizumab, Abatacept) within 12 months prior to inclusion
- with contraindications for a booster vaccination against tetanus toxoid: o Hypersensitivity to the active substance(s) or to any of the excipients o Severe reaction after previous administration with the same vaccine
- who received a TT vaccination or booster within the past 24 months prior to inclusion
- who do not fulfill the classification criteria for the respective diagnoses, as set out in the inclusion criteria
- for whom the treating physician considers that relevant safety issues apply (such as, for example, severe anemia) that preclude the provision of the required amount of peripheral blood projected for the study
- who need to donate 50 mL of blood (or more) during the first four weeks of the study for any reason other than participation in the study (such as routine clinical care, participation in another study, blood donations for the blood bank, etc.)
- who are pregnant at the time of inclusion
Where in Netherlands
- Leids Universitair Medisch Centrum (LUMC)Leiden, NetherlandsNot yet recruiting
About the trial
What the trial wants to find out
To induce, by booster vaccination, the activation of TT-specific B cells in order to compare the autoreactive B cell compartment with the resting and activated TT-specific B cell compartment over time in patients with autoimmune diseases and healthy individuals.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Investigating the (autoreactive) B cell compartment in antibody-mediated autoimmune diseases in comparison with the recall Tetanus Toxoid response
- Plain-language title
- Tetanus booster vaccine to study immune cells in autoimmune disease patientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 8 July 2025